Omega-3 Fatty Acids
Essential polyunsaturated fats (EPA/DHA) supporting cardiovascular, brain, and inflammatory health.
Evidence Summary
Extensive RCT data for cardiovascular outcomes (REDUCE-IT). Well-established anti-inflammatory effects. Critical for brain health. UPDATE (August 2026): A systematic review of nutritional interventions and cellular senescence in humans (Ageing Research Reviews 2026; 27 trials, 3,811 participants) found that among dietary supplements, n-3 polyunsaturated fatty acids were the only class showing plausible modulation of selected inflammatory and SASP-related circulating markers - though the authors describe supplement evidence overall as limited and heterogeneous, and note that SASP-panel cytokines are not specific to senescent cells. This is consistent with, and adds mechanistic texture to, the established anti-inflammatory profile of omega-3s. It is not evidence that omega-3 supplementation reduces senescent-cell burden. UPDATE (October 2026): The DO-HEALTH Bio-Age analysis (Bischoff-Ferrari et al., Nature Aging 2025; n=777 adults aged 70+, 3 years) found that 1 g/day of omega-3 (330 mg EPA + 660 mg DHA) was associated with a small but consistent slowing of three next-generation DNA-methylation aging clocks versus placebo: GrimAge2 (-0.32 SD, 95% CI -0.06 to -0.59), DunedinPACE (-0.17 SD, 95% CI -0.04 to -0.31; ~1% slower pace of aging) and PhenoAge (-0.16 SD, 95% CI -0.02 to -0.30) - roughly 3-4 months less biological aging over 3 years. Adding vitamin D and strength training gave additive benefit on PhenoAge only; older clocks (Horvath, Hannum) and vitamin D or exercise alone showed no clear effect. Important context: the parent DO-HEALTH randomized trial (JAMA 2020, n=2,157) found that none of the three interventions significantly improved its primary clinical endpoints - blood pressure, non-vertebral fractures, physical function, cognition or infections - in generally healthy older adults. The epigenetic-clock result is a small, post hoc, surrogate-marker finding that is hypothesis-generating, not proof that omega-3 extends healthy lifespan. Omega-3's best-established benefits remain cardiovascular risk reduction and triglyceride lowering.
Evidence Scale
Mechanism of Action
Incorporated into cell membranes, modulating fluidity. Precursors to anti-inflammatory resolvins and protectins. Support cardiovascular, neurological, and immune function.
Who Is This For?
Cardiovascular risk, inflammation, cognitive support, mood disorders. Omega-3 index testing available.
Protocol & Dosing
Dose
2-4g combined EPA/DHA daily. Higher EPA for inflammation, balanced for general health.
Frequency
Daily with meals
Duration
Ongoing
Protocol Summary
Triglyceride or ethyl ester form. Take with food. EPA:DHA ratio varies by goal.
Latest Evidence
2025: DO-HEALTH links 1 g/day omega-3 to slower epigenetic aging
In the DO-HEALTH Bio-Age analysis (Bischoff-Ferrari et al., Nature Aging 2025), 777 adults aged 70+ taking 1 g/day of omega-3 (330 mg EPA + 660 mg DHA) for three years showed a small but consistent slowing of three next-generation DNA-methylation aging clocks versus placebo — GrimAge2 (−0.32 SD), DunedinPACE (−0.17 SD, about 1% slower pace of aging) and PhenoAge (−0.16 SD), roughly equivalent to 3–4 months less biological aging over three years. Adding vitamin D and strength training produced additive benefit on PhenoAge. Older clocks (Horvath, Hannum) and vitamin D or exercise alone showed no clear effect.
Important context: the parent DO-HEALTH randomized trial (JAMA 2020, n=2,157) found that none of the three interventions significantly improved its primary clinical endpoints — blood pressure, non-vertebral fractures, physical function, cognition or infections — in generally healthy older adults. The epigenetic-clock result is a small, post hoc, surrogate-marker finding that is hypothesis-generating, not proof that omega-3 extends healthy lifespan. Omega-3's best-established benefits remain cardiovascular risk reduction and triglyceride lowering; high doses can raise bleeding risk and a modest atrial-fibrillation signal has been reported. Individualize and target an omega-3 index >8% by testing. Educational information, not medical advice.
DO-HEALTH Bio-Age · n=777 · 1 g/day omega-3 · 3-yr RCT
Omega-3 slowed three DNA-methylation aging clocks
Source: Bischoff-Ferrari et al., Nature Aging 2025 — DO-HEALTH Bio-Age analysis (n=777; 1 g/day omega-3 [330 mg EPA + 660 mg DHA]; 3 years). Standardized reductions vs. placebo: GrimAge2 −0.32 (95% CI −0.06 to −0.59), DunedinPACE −0.17 (−0.04 to −0.31), PhenoAge −0.16 (−0.02 to −0.30) — roughly 3–4 months less biological aging over 3 years. This is a small, post hoc, surrogate-marker effect; the parent DO-HEALTH trial (JAMA 2020) found no significant benefit on primary clinical endpoints. Educational information, not medical advice.
Related on Peak Human
Omega-3 Fish Oil
The supplement form — EPA/DHA sourcing, forms and dosing.
Omega-3 Index
The red-blood-cell biomarker to target above 8%.
EPA, DHA & DPA Explained
How the three marine omega-3s differ and why it matters.
Krill Oil vs. Fish Oil
Absorption and phospholipid vs. triglyceride forms.
Diagnostic Testing
Measure your omega-3 index before and during supplementation.
Peak Human Shop
Practitioner-grade, third-party-tested omega-3.
Key references: Omega-3, vitamin D & exercise on DNA-methylation clocks — DO-HEALTH, Nature Aging (2025) · DO-HEALTH randomized trial: clinical outcomes in adults ≥70 — JAMA (2020) · Omega-3 fatty acids & cardiovascular outcomes: systematic review & meta-analysis — EClinicalMedicine (2021)
Interactions & Precautions
Contraindications
- Fish allergy (fish-derived)
- Anticoagulation (high doses)
Potential Risks
- •Oxidation if poor quality
- •Bleeding risk at high doses
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Triglyceride form superior absorption. Check for third-party testing. Target omega-3 index >8%. EPA dominant for cardiovascular/inflammatory goals. Updated August 2026: Omega-3s were the only supplement class in the 2026 human senescence systematic review to show plausible movement on SASP-related circulating markers. Worth noting to patients interested in senescence, with the caveat the authors themselves apply - these markers are not senescent-cell-specific, so this supports the anti-inflammatory case rather than a senolytic one. Primary indication remains cardiovascular and cognitive. Updated October 2026: The 2025 DO-HEALTH Bio-Age analysis adds a plausible aging-biology signal (slowed GrimAge2/DunedinPACE/PhenoAge on 1 g/day) to omega-3's established anti-inflammatory profile, but the parent trial was null on hard clinical endpoints - frame to patients as supportive, surrogate-marker evidence rather than a longevity guarantee. Primary, best-evidenced indications remain cardiovascular risk reduction (notably high-dose EPA) and hypertriglyceridemia; mind bleeding risk and the modest atrial-fibrillation signal at high doses. Continue to target an omega-3 index >8% and titrate to labs.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
